Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NYSE: NXTC) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer and immune disorders. This page provides centralized access to official news and developments surrounding their innovative pipeline, including antibody-drug conjugates and fusion protein therapies targeting complex tumor microenvironments.
Investors and researchers will find timely updates on clinical trial progress, strategic collaborations, and regulatory milestones. Key focus areas include NC410 combination therapies for immune modulation and the B7-H4-targeting LNCB74 ADC program. The curated news collection also covers financial disclosures, manufacturing advancements, and scientific presentations.
All content is sourced directly from company releases and verified industry publications. Bookmark this page to monitor NextCure's progress in developing first-in-class immunomedicines and their expanding research into neurodegenerative and chronic disease applications.
NextCure (Nasdaq: NXTC) announced promising results from its Phase 1b study of NC410 in combination with pembrolizumab, presented at ASCO 2024. The study focused on patients with MSS/MSI-L colorectal cancer (CRC) and ovarian cancer. Key findings include a 51% disease control rate in CRC patients and a 43% rate in ovarian cancer patients. Two CRC patients had ongoing partial responses (PR) and a median disease control duration of 5.5 months. In ovarian cancer, three patients experienced PRs with a 43% overall response rate. Adverse events were mostly mild, but 39.5% of patients had Grade ≥3 Treatment Emergent Adverse Events (TEAE), and 4.9% had Grade ≥3 Treatment-Related Adverse Events (TRAE). A poster presentation by Dr. Eric S. Christenson will detail these findings on June 1, 2024, at the ASCO Annual Meeting in Chicago.
NextCure, a clinical-stage biopharmaceutical company, reported its first-quarter 2024 financial results and provided a business update. They highlighted presenting Phase 1b data for NC410 combo with pembro at the ASCO Annual Meeting, showcasing preclinical data from LNCB74 at the AACR Annual Meeting, and having cash of approximately $96.0 million to fund operations into the second half of 2026. The company is focused on developing novel cancer therapies.
FAQ
What is the current stock price of Nextcure (NXTC)?
What is the market cap of Nextcure (NXTC)?
